$WALDJun 15, 2026, 1:02 PMAI processed
FDA approves Obagi saypha ChIQ hyaluronic-acid filler for cheek augmentation
AI Summary
Waldencast (WALD) announced FDA approval of Obagi saypha ChIQ, a hyaluronic-acid injectable indicated for cheek augmentation and correction of midface contour deficiencies in adults 21+. The product, developed with Croma‐Pharma using proprietary MACRO Core Technology, expands Obagi Medical's injectable portfolio and could boost cross‐sell into Obagi skincare following strong provider feedback from the recent saypha MagIQ launch; the company did not disclose launch timing, pricing, or pivotal clinical data for ChIQ.
Positives
- FDA approval granted for Obagi saypha ChIQ for cheek augmentation/midface contouring in patients 21+
- Product leverages Croma‑Pharma's MACRO Core Technology and an established manufacturing partner with large global syringe volumes
- Builds on momentum from the recent saypha MagIQ launch and ALOHA real‑world program that showed strong provider interest and potential skincare attachment rates
Negatives
- No commercial launch date, pricing, or U.S. supply details disclosed
- Approval is limited to cheek augmentation/midface—narrow indication versus full‑face filler claims
- Press release did not include pivotal clinical efficacy/safety data specific to ChIQ